2- (3- benzoyl)- 4- hydroxy- 1,1- dioxo- 2H- 1,2- benzothiazine- 2- yl- 1- phenylethanone

an antidiabetic agent and 11beta-hydroxysteroid dehydrogenase type 1 inhibitor; structure in first source

Also Known As:

KR 66344; KR-66344; KR66344

Networked: 3 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Sulfur Compounds: 278
  - Thiazines: 3
    - 2-(3-benzoyl)-4-hydroxy-1,1-dioxo-2H-1,2-benzothiazine-2-yl-1-phenylethanone: 3
  - Cyclic S-Oxides
    - 2-(3-benzoyl)-4-hydroxy-1,1-dioxo-2H-1,2-benzothiazine-2-yl-1-phenylethanone: 3
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Thiazines: 3
    - 2-(3-benzoyl)-4-hydroxy-1,1-dioxo-2H-1,2-benzothiazine-2-yl-1-phenylethanone: 3
- Heterocyclic Oxides
  - Cyclic S-Oxides
    - 2-(3-benzoyl)-4-hydroxy-1,1-dioxo-2H-1,2-benzothiazine-2-yl-1-phenylethanone: 3

Experts

1.	Ahn, Jin Hee: 2 articles (08/2016 - 04/2011)
2.	Jung, Won Hoon: 2 articles (08/2016 - 04/2011)
3.	Kim, Hee Youn: 2 articles (08/2016 - 04/2011)
4.	Kim, Ki Young: 2 articles (08/2016 - 04/2011)
5.	Park, Ji Seon: 2 articles (08/2016 - 04/2011)
6.	Choi, Kyoung-Jin: 1 article (08/2016)
7.	Choi, Sunhwa: 1 article (08/2016)
8.	Dal Rhee, Sang: 1 article (08/2016)
9.	Kwak, Hyun Jung: 1 article (08/2016)
10.	Na, Yoon-Ju: 1 article (08/2016)

Related Diseases

1.	Glucose Intolerance 04/15/2011 - "In the C57BL/6-Lep(ob/ob) mice study, the administration of KR-66344 (200mg/kg/d, orally for 5 days) improved the glucose intolerance as determined by the oral glucose tolerance test, in which the area under the curve (AUC) of the plasma glucose concentration was significantly reduced by 27% compared with the vehicle treated group. "
2.	Metabolic Syndrome (Dysmetabolic Syndrome X) 04/15/2011 - "Taken together, these results may provide evidence of the therapeutic potential of KR-66344, as a 11β-HSD1 inhibitor, in obesity and type 2 diabetes patients with metabolic syndrome." 05/01/2014 - "2-(3-Benzoyl)-4-hydroxy-1,1-dioxo-2H-1,2-benzothiazine-2-yl-1-phenylethanone (KR-66344), a 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor, is newly developed for the control of type 2 diabetes mellitus (T2DM) and metabolic syndrome. "
3.	Type 2 Diabetes Mellitus (MODY) 04/15/2011 - "Taken together, these results may provide evidence of the therapeutic potential of KR-66344, as a 11β-HSD1 inhibitor, in obesity and type 2 diabetes patients with metabolic syndrome." 05/01/2014 - "2-(3-Benzoyl)-4-hydroxy-1,1-dioxo-2H-1,2-benzothiazine-2-yl-1-phenylethanone (KR-66344), a 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor, is newly developed for the control of type 2 diabetes mellitus (T2DM) and metabolic syndrome. "
4.	Obesity 04/15/2011 - "Taken together, these results may provide evidence of the therapeutic potential of KR-66344, as a 11β-HSD1 inhibitor, in obesity and type 2 diabetes patients with metabolic syndrome."
5.	Inflammation (Inflammations) 08/01/2016 - "Taken together, KR-66344 protects against LPS-induced animal death and spleen injury by inhibition of inflammation via induction of HO-1 and inhibition of 11β-HSD1 activity. " 08/01/2016 - "In the spleen of LPS-treated mice, KR-66344 prevented cell death via suppression of inflammation, followed by inhibition of ROS, iNOS and COX-2 expression. "

Related Drugs and Biologics

1.	Glucose (Dextrose)
2.	Oxidoreductases (Dehydrogenase)